Human CD34+ Hematopoietic Stem Cell from Bone Marrow (HHSC-BM) or Liver (HHSC-L) contain CD34+ progenitor cells that differentiate into all the various blood cell types. Cells are only guaranteed with the purchase of Ace Therapeutics's Media and Ace Therapeutics's Extra Cellular Matrix for appropriate cell culture, for 30 days from the date of shipment.

Human Umbilical Cord Blood Mononuclear Cells are a mixture of various cell populations with a single nucleus, including hematopoietic and mesenchymal stem cells, endothelial progenitor cells, lymphocytes, and monocytes. They can be induced to differentiate into neuron cells, osteoblasts, and lymphocytes. Human Umbilical Cord Blood Mononuclear Cells from Ace Therapeutics are isolated from umbilical cord blood. Cells are isolated by density gradient separation and cryopreserved immediately to ensure the best viability. Human Umbilical Cord Blood Mononuclear Cells are quality tested with less than 2% red blood cells.

Human Cord Blood-CD34+ Hematopoietic Stem Cell from Ace Therapeutics are isolated using positive magnetic isolation of CD34 from cord blood. CD34+ cells are targeted using uniform, superparamagnetic polymer beads coated with a primary monoclonal antibody specific for the CD34 membrane antigen predominantly expressed on human hematopoietic progenitor cells and endothelial progenitor cells. The isolated cells are poured off into a new tube and are cryogenically preserved.

Human Mesenchymal Stem Cells from Placenta (hPSCs) from Ace Therapeutics are human mesenchymal stem cells (hMSC) isolated from placental tissue, specifically from amnion, decidua, or chorion villi. MSC have been shown to differentiate in vitro into adipocytes, chondrocytes, osteoblasts, myocytes, and β-pancreatic islets cells. They can also transdifferentiate into neuronal cells and hepatocytes.

Human iPSC-derived Astrocytes from Ace Therapeutics is derived from integration-free, induced pluripotent stem cells (iPSCs) under fully defined growth conditions using a completely reproducible process.

Human iPSC From Adipose Mesenchymal Stromal Cells from Ace Therapeutics are generated using an episomal reprogramming containing a proprietary mix of vectors, containing Oct-4, Sox-2, Klf-4 along with p53 Anti-sense, EBNA-1. The cell line was validated for pluripotency based on colony morphology, alkaline phosphatase expression, and expression of SSEA-4.iPS colonies exhibit classical morphology and growth.

Human Placental Derived Mesenchymal Stem Cell are a well-characterized population of adult stem cells. These adult stem cells have a broad therapeutic potential due to their capability to renew and differentiate into various lineages of mature cells that produce fat, cartilage, bone, tendon, and muscle when cultured under specific permissive conditions. These cells are expanded in a Mesenchymal Stem Cell Medium and then cryopreserved at passage 2. The human placental MSC express typical mesenchymal cell surface markers, such as CD105, CD73, and CD90 and are negative for hematopoietic markers including CD34, CD45, and endothelial cell marker CD31.

Human reprogrammed iPSC Cells established from endothelial progenitor cells that derived from peripheral blood.

Human iPSC-Derived Neural Stem Cells are a homogeneous and multipotent population derived from control Human Induced Pluripotent Stem Cells.

Human Bone Marrow CD133+ Stem/Progenitor Cells from Ace Therapeutics are isolated using positive immunomagnetic cell separation procedures from bone marrow. Capable of a high level of proliferation and a wide range of differentiation, transplantation of bone marrow CD133+ cell lines has been shown to not only induced multilineage human hematopoiesis through the CD34+ lineage but also induce regeneration of cell lines in vitro in multiple locations by differentiating into endothelial cells, neural cells, hepatocytes, osteoblasts, and myocytes, with the list of tissue types this cell can differentiate into gradually increasing.